Summary
Lisinopril (MK521), a lysine analogue of enalaprilic acid, the bioactive metabolite of enalapril, has a longer half-life than enalaprilic acid, and is excreted unchanged in the urine. Its kinetic profile and antihypertensive and hormonal effects have been investigated in an open study in 3 groups each of 6 hypertensive patients, with normal, moderate and severe impairment of renal function. Serum drug level, blood pressure, converting enzyme activity (CEA), plasma renin activity (PRA), aldosterone concentration (PAC), and serum potassium and creatinine were measured during 1 week following a single oral dose and subsequently following 8 daily doses of 5 mg lisinopril. Accumulation of lisinopril was found in the severe renal failure group. CEA was suppressed to less than 10% of its initial value from 4 to 24 h after the initial dose in all three groups, and the suppression was more marked and lasted longer in patients with severe renal failure. An inverse correlation was found in all patients between log serum lisinopril concentration and log CEA. Lisinopril lowered blood pressure in all three groups over 24 h. PRA rose and PAC fell similarly in the groups. Serum potassium increased in the renal failure groups and creatinine remained unchanged in all groups.
Thus, when lisinopril 5 mg is given daily to patients with severe renal failure it may accumulate. The high serum lisinopril concentration does not cause an excessive antihypertensive effect. In patients with severe renal failure, adjustment of the dose or the dosing frequency to the degree of renal failure is recommended to avoid administration of doses in excess of those required to achieve adequate inhibition of converting enzyme.
Similar content being viewed by others
References
Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL (1981) Effect of a new angiotensin converting enzyme inhibition MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol 11: 461–467
Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO (1981) Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 2: 543–547
Sweet CS, Gross DM, Arbegast PI, Gaul SL, Britt PM, Ludden CT, Weits D, Stone CA (1981) Antihypertensive activity of N-[(s)-1-(ethoxycarbonyl)-3-phenyl-propyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 216: 558–566
Ulm EH, Hichens M, Gomez HJ, Till EA, Hand EL, Vassil TC, Biollaz J, Brunner HR, Schelling JL (1982) Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmacol 14: 357–362
Millar JA, Derkx FHM, McLean K, Reid JL (1982) Pharmacodynamics of converting enzyme inhibition: The cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol 14: 347–355
Ajayi AA, Campbell BC, Howie CA, Reid JL (1985) Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens 3: 47–53
Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR (1985) Once daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system. Curr Ther Res 37: 342–351
Rotmensch HH, Vlasses PH, Swanson BN, Irvin JD, Harris KE, Merrill DG, Ferguson RK (1984) Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol 53: 115–119
Biollaz J, Schelling JL, Jacot des Combes B, Brunner DB, Desponds G, Brunner HR, Ulm EH, Hichens M, Gomez HJ (1982) Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 14: 363–368
Boer P, Hené RJ, Koomans HA, Nieuwenhuis MG, Geyskes GG, Dorhout Mees EJ (1983) Blood and extracellular fluid volume in patients with Bartter's syndrome. Arch Intern Med 143: 1902–1905
Hurst PL, Lovell-Smith CJ (1981) Optimized assay for serum angiotensin converting enzyme activity. Clin Chem 27: 2048–2052
Hichens M, Hand EL, Mulcahy WS (1981) Radioimmunoassay for angiotensin converting enzyme inhibitors. Ligand Quaterly 4: 43
Kelly JG, Doyle G, Donohue J, Laher M, Vandenburg MJ, Currie WJC, Cooper WD (1986) Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol 21: 63–69
Johnston CI, Jackson BJ, Larmour I, Cubella R, Casley D (1984) Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Br J Clin Pharmacol 18: 233s-239s
Hodsman GP, Zabludowski JR, Zoccali C, Fraser R, Morton JJ, Murray GD, Robertson JIS (1984) Enalapril (MK421) and its lysine analogue (MK521): A comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol 17: 233–241
Bauer JH, Jones LB (1984) Comparative studies: Enalapril versus hydrochlorothiazide as first step therapy for the treatment of primary hypertension. Am J Kidney Dis 4: 55–62
McNabb WR, Noormohamed FH, Lant AF (1986) The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance. J Hypertens 4: 39–47
McNabb WR, Noormohamed FH, Brooks BA, Till AE, Lant AF (1985) Effects of repeated doses of enalapril on renal function in man. Br J Clin Pharmacol 19: 353–361
Zanelli MT, Mattei E, Draibe SA, Kater CE, Ajzen H (1985) Inadequate aldosterone response to hyperkaliemia during angiotensin converting enzyme inhibition in chronic renal failure. Clin Pharmacol Ther 38: 613–617
Hollenberg NK, Swartz SL, Passan DR, Williams GH (1979) Increased glomerular filtration rate after converting enzyme inhibition in essential hypertension. N Engl J Med 301: 9–12
Simon AC, Levenson J, Bouthier JD, Safar ME (1985) Effects of chronic administration of enalapril and propranolol of the large arteries in essential hypertension. J Cardiovasc Pharmacol 7: 856–861
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Schaik, B.A.M., Geyskes, G.G. & Boer, P. Lisinopril in hypertensive patients with and without renal failure. Eur J Clin Pharmacol 32, 11–16 (1987). https://doi.org/10.1007/BF00609951
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609951